BCAAs are associated with increased risk for T2D in adults, while glycine (Gly) appears to be have an inverse relationship. β-cell function is central to the development of T2D in youth. The relationship of Gly and BCAA to β-cell function in youth is not clear.

We investigated the relationship between Gly vs. the BCAA: Leucine (Leu) , Isoleucine (Ile) and Valine (Val) , to insulin sensitivity (IS) and β-cell function in youth across the spectrum of glycemia.

Adolescents (65 female/62 male; 15.5±1.9 y.o.; 30 with normal weight normal glucose tolerance (NW-NGT) , 33 obese-NGT, 34 prediabetes, and 30 T2D) underwent assessment of AA concentrations (mass spectrometry) , fasting and at steady state (SS) of a 3-hr hyperinsulinemic-euglycemic clamp (in-vivo IS) ; insulin secretion by 2-hr hyperglycemic clamp; adipokines, body composition (DXA) and visceral fat (MRI) . The disposition index (DI) (measure of β-cell function) = first phase insulin x IS per fat free mass (DIFFM) . We performed analysis of variance (adjusting for sex, race-ethnicity and Tanner stage) and correlation analyses.

Fasting and SS-Gly were lower and SS-BCAA higher in the groups with obesity compared with NW with post-hoc significant differences in T2D vs. NW (p<0.0for fasting and SS-Gly, SS-Ile, and p=0.02 for SS-Val) and in prediabetes vs. NW (for Gly, Val and Ile) . Fasting and SS-Gly negatively and SS-BCAA positively associated with %body fat, waist/hip, and visceral fat, while Gly positively and BCAA negatively related to adiponectin. Fasting and SS-Gly (r=0.4, p<0.001) positively and SS-BCAA (r=-0.4 for Val, Leu, Ile, p<0.001) negatively related to ISFFM. Gly positively (r=0.27, p=0.005) , SS-Ile (r=-0.26, p=0.006) inversely related to DIFFM.

Gly is positively related to IS and β-cell function and negatively to adiposity measures, with opposite relationships observed for BCAA. A metabolic signature of low Gly and elevated BCAA may constitute a biomarker to identify youth at risk for β-cell failure.

Disclosure

H.El ayash: None. M.A.Mohammad: None. R.S.Shawar: None. R.S.Kanchi: None. S.Sharma: None. M.R.Puyau: None. C.Coarfa: None. F.Bacha: Other Relationship; AstraZeneca, Takeda Pharmaceutical Company Limited, Research Support; National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Department of Agriculture.

Funding

USDA-ARS

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.